- Home
- GLMD vs SNOA Comparison
GLMD vs SNOA Comparison
Compare GLMD & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- SNOA
- Stock Information
- Founded
- GLMD 2000
- SNOA 1999
- Country
- GLMD Israel
- SNOA United States
- Employees
- GLMD N/A
- SNOA N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- GLMD Health Care
- SNOA Health Care
- Exchange
- GLMD Nasdaq
- SNOA Nasdaq
- Market Cap
- GLMD 8.0M
- SNOA 7.5M
- IPO Year
- GLMD 2014
- SNOA 2007
- Fundamental
- Price
- GLMD $1.59
- SNOA $4.22
- Analyst Decision
- GLMD Hold
- SNOA
- Analyst Count
- GLMD 1
- SNOA 0
- Target Price
- GLMD N/A
- SNOA N/A
- AVG Volume (30 Days)
- GLMD 81.5K
- SNOA 45.9K
- Earning Date
- GLMD 11-13-2025
- SNOA 11-06-2025
- Dividend Yield
- GLMD N/A
- SNOA N/A
- EPS Growth
- GLMD N/A
- SNOA N/A
- EPS
- GLMD N/A
- SNOA N/A
- Revenue
- GLMD N/A
- SNOA $14,912,000.00
- Revenue This Year
- GLMD N/A
- SNOA $23.00
- Revenue Next Year
- GLMD N/A
- SNOA $24.59
- P/E Ratio
- GLMD N/A
- SNOA N/A
- Revenue Growth
- GLMD N/A
- SNOA 17.43
- 52 Week Low
- GLMD $1.15
- SNOA $1.75
- 52 Week High
- GLMD $4.81
- SNOA $6.92
- Technical
- Relative Strength Index (RSI)
- GLMD 58.87
- SNOA 50.01
- Support Level
- GLMD $1.35
- SNOA $3.72
- Resistance Level
- GLMD $1.63
- SNOA $4.60
- Average True Range (ATR)
- GLMD 0.09
- SNOA 0.21
- MACD
- GLMD 0.02
- SNOA 0.00
- Stochastic Oscillator
- GLMD 76.67
- SNOA 50.00
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.